Connection
Gregory Schwartz to Hyperlipoproteinemia Type III
This is a "connection" page, showing publications Gregory Schwartz has written about Hyperlipoproteinemia Type III.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.245 |
|
|
|
-
Geba GP, Mohammadi KA, Damask A, Paulding C, Lotta LA, Hindy G, Pordy R, Manvelian G, Shapiro MD, Bittner VA, Bhatt DL, Szarek M, Schwartz GG, Steg PG, Fazio S. Effect of PCSK9 Inhibition With Alirocumab in Patients With Probable Familial Hypercholesterolemia or Type III Hyperlipoproteinemia: Results From the ODYSSEY OUTCOMES Trial. J Am Heart Assoc. 2025 Sep 02; 14(17):e041190.
Score: 0.245